EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

Employees

Sector

Biotechnology & Medical Research

More about the company

04-30	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/08/25	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	17.31M 21.41M 18.75M 16.16M 30.42M 2.02B 31.12M 208M 80.41M 999M 80.41M 78.65M 3.47B	P/E 2024	6.22x	P/E 2025	-8.95x
Enterprise Value	11.4M 14.11M 12.35M 10.65M 20.04M 1.33B 20.5M 137M 52.97M 658M 52.97M 51.81M 2.28B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	58.74%	Yield 2024 *	-	Yield 2025	-

04-30	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/08/25	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/07/25	Evolva Shareholders OK Proposed Renaming to EvoNext	MT
25/07/25	Evolva Holding SA has Changed its Name to EvoNext Holdings SA	CI
23/07/25	Evolva to Not Receive Earn-out Payments from Unit's Buyer	MT
03/07/25	Evolva Directors Propose Change of Name to EvoNext	MT
04/06/25	Evolva Seeks Dialogue with Swiss Hospital Shareholders on Takeover Bid	MT
27/05/25	Evolva Offers to Buy Hospital in Switzerland	MT
21/02/25	Evolva Swings to FY24 Net Profit	MT
21/02/25	Evolva Holding SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
21/02/25	Evolva Holding SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
04/02/25	Evolva Holding: Shareholder Clearway Requests General Meeting	RE
30/12/24	Swiss Stocks Close Higher Ahead of New Year Break	MT

05-20	EvoNext : Minutes of Annual General Meeting 2026	PU
05-20	EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026	EQ
04-29	EvoNext : Invitation to AGM 2026 E	PU
04-29	EvoNext : (2025 12 EvoNext Holdings SA Annual Report 2025)	PU
04-29	EvoNext Holdings SA publishes full-year report 2025	EQ

05-20	Evonext-Aktionäre stimmen an GV allen Anträgen zu
04-29	Evonext poursuit ses recherches, forte d'une assise financière solide
04-29	Evonext weist solide Kapitalbasis aus - Suche für Reverse Takeover läuft weiter
04-29	EvoNext : Einladung zur Generalversammlung 2026 DE
21/08/25	Evonext (ex-Evolva) a consumé des liquidités au premier semestre

ARPIDA Stock Swiss Exchange

Stocks

ARPN

Biotechnology & Medical Research

Valuation: ARPIDA

Latest news : ARPIDA

Analysts' recommendations: ARPIDA

Press Releases: ARPIDA

News in other languages: ARPIDA

Managers and Directors: ARPIDA

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Francesco Defila BRD	Director/Board Member	-	27/03/2025
Gianluca Ferrari CHM	Chairman	-	27/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.94%	+7.83%	-4.50%	+3.17%	46.2B
REVOLUTION MEDICINES, INC.	+3.11%	+12.54%	+407.23%	+611.71%	38.71B
IQVIA HOLDINGS INC.	+0.28%	+14.11%	+21.51%	-13.52%	31.9B
BEONE MEDICINES AG	+2.95%	+5.60%	+18.56%	+60.71%	31.12B
CELLTRION, INC.	+8.02%	+5.23%	+17.67%	+35.36%	23.77B
ASCENDIS PHARMA A/S	+1.08%	+15.74%	-	-	16.2B
MEDPACE HOLDINGS, INC.	-0.31%	+15.39%	+67.52%	+123.80%	15.05B
EUROFINS SCIENTIFIC SE	-1.13%	+7.40%	+12.81%	+20.67%	13.74B
IONIS PHARMACEUTICALS, INC.	-0.42%	+6.28%	+104.14%	+96.19%	13.42B
Average	+1.54%	+10.60%	+80.62%	+117.26%	25.57B
Weighted average by Cap.	+1.81%	+10.07%	+92.70%	+138.20%

	2024	2025
Net sales	-	-
Net income	1.04M 1.29M 1.13M 975K 1.83M 122M 1.88M 12.56M 4.85M 60.23M 4.85M 4.74M 209M	-653K -807K -707K -610K -1.15M -76.34M -1.17M -7.85M -3.03M -37.66M -3.03M -2.97M -131M
Net Debt	-6.75M -8.35M -7.32M -6.31M -11.87M -790M -12.14M -81.27M -31.37M -390M -31.37M -30.69M -1.35B	-5.91M -7.31M -6.4M -5.51M -10.38M -691M -10.62M -71.07M -27.44M -341M -27.44M -26.83M -1.18B

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-